1. Search Result
Search Result
Results for "

IgG1-κ

" in MedChemExpress (MCE) Product Catalog:

75

Inhibitors & Agonists

209

Inhibitory Antibodies

15

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9997

    ANB030

    PD-1/PD-L1 Cancer
    Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 [1] .
    Rosnilimab
  • HY-P9993

    LY-3462817

    PD-1/PD-L1 Cancer
    Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis [1] .
    Peresolimab
  • HY-P9999

    RG6102; RO-7126209

    Amyloid-β Neurological Disease
    Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar as well as plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 [1] .
    Trontinemab
  • HY-P99892

    PR-1594407; DC-1630423

    EGFR Others
    Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells [1].
    Serclutamab
  • HY-P99728

    RG7835; RO7049665

    Interleukin Related Inflammation/Immunology
    Melredableukin alfa (RO-7049665) is a fusion protein that consists of a human IgG1-κ fused to a mutated human interleukin 2 (IL2 mutein) via a peptide linker. Melredableukin alfa can be used for the research of autoimmune hepatitis and ulcerative colitis [1].
    Melredableukin alfa
  • HY-P9988

    BA301

    ADC Antibody TAM Receptor Cancer
    Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) [1] .
    Mecbotamab
  • HY-P99888

    EGFR Others
    Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells [1].
    Pimurutamab
  • HY-P990038

    Phosphatase Neurological Disease
    Eurestobart is a humanized IgG1κ antibody targeting ENTPDase.
    Eurestobart
  • HY-P990780

    Transferrin Receptor Inflammation/Immunology
    Zeleciment is an anti-TFRC IgG1κ monoclonal antibody [1].
    Zeleciment
  • HY-P99864

    ZTS-00521505

    Interleukin Related Others
    Dovanvetmab (ZTS-00521505) is an IgG1-κ antibody targeting Felcat IL31. Mainly expressed by CHO (Chinese Hamster Ovary) cells [1].
    Dovanvetmab
  • HY-P99104

    COVI-AMG; STI-2020

    SARS-CoV Infection
    Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) [1] .
    Plutavimab
  • HY-P990057

    Interleukin Related Cancer
    Picankibart is a mouse-derived IgG1κ antibody targeting IL23A [1].
    Picankibart
  • HY-P990024

    SRF-388

    Interleukin Related Cancer
    Casdozokitug (SRF-388) is an IgG1κ antibody targeting IL27 [1].
    Casdozokitug
  • HY-P990689

    RO-7250284

    VEGFR Inflammation/Immunology
    Zifibancimig is an anti-VEGFA/ANGPT2 IgG1κ monoclonal antibody [1].
    Zifibancimig
  • HY-P99699

    MHAB5553A; RG70026

    Influenza Virus Infection
    Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody [1].
    Lesofavumab
  • HY-P9995

    JNJ-63733657

    Tau Protein Cancer
    Posdinemab is a humanized IgG1κ antibody, targeting to microtubule-associated protein tau (MAPT) [1].
    Posdinemab
  • HY-P9909
    Ustekinumab
    1 Publications Verification

    Anti-Human IL-12/IL-23, Human Antibody

    Interleukin Related Inflammation/Immunology Cancer
    Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
    Ustekinumab
  • HY-P990036

    IFNAR Infection
    Dazukibart is a mouse-derived, humanized IgG1κ antibody targeting interferon beta 1 (IFNB1) [1].
    Dazukibart
  • HY-P990082

    VEGFR Cancer
    Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) [1].
    Suvemcitug
  • HY-P990007

    PRA023; PRA-023

    TNF Receptor Inflammation/Immunology
    Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) [1] .
    Tulisokibart
  • HY-P99368

    MCS110; Anti-Human B7-H3

    c-Fms Metabolic Disease Cancer
    Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis [1] .
    Lacnotuzumab
  • HY-P990040

    LVGN-6051

    TNF Receptor Cancer
    Exlinkibart (LVGN-6051) targets TNFRSF9 and is an IgG1κ antibody humanized through complementarity-determining region (CDR) grafting technology.
    Exlinkibart
  • HY-P990041

    CTLA-4 Inflammation/Immunology Cancer
    Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer [1].
    Firastotug
  • HY-P990052

    MAD-0004J08

    SARS-CoV Infection
    Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain [1].
    Simaravibart
  • HY-P99040

    JNJ-61610588

    PD-1/PD-L1 Cancer
    Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity [1].
    Onvatilimab
  • HY-P99310

    RG4934

    Interleukin Related Inflammation/Immunology
    Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis [1].
    Perakizumab
  • HY-P99315

    BG 9588; Anti-Human CD40L Recombinant Antibody

    TNF Receptor Inflammation/Immunology
    Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research [1].
    Ruplizumab
  • HY-P99181

    CPI-006

    CD73 Infection Inflammation/Immunology Cancer
    Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 POS B cells [1].
    Mupadolimab
  • HY-P990716

    PD-1/PD-L1 Inflammation/Immunology
    Sabestomig is an anti-PDCD1/HAVCR2 Ig(G1G1-λ2) monoclonal antibody [1].
    Sabestomig
  • HY-P99952

    SCT400

    CD20 Cancer
    Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) [1].
    Ripertamab
  • HY-P9901
    Ipilimumab
    4 Publications Verification

    MDX-010; BMS-734016

    CTLA-4 Cancer
    Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies [1].
    Ipilimumab
  • HY-P99424

    RG 7624; RO 5553110; NI-1401

    Interleukin Related Inflammation/Immunology
    Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities [1].
    Afasevikumab
  • HY-P990046

    Incagn-02385

    LAG-3 Inflammation/Immunology
    Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells [1].
    Tuparstobart
  • HY-P99733

    ADC Antibody TAM Receptor Cancer
    Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity [1].
    Mipasetamab
  • HY-P99544

    HBM-9167; KL-A167

    PD-1/PD-L1 Cancer
    Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) [1] .
    Tagitanlimab
  • HY-P99669

    MDX-060

    TNF Receptor Cancer
    Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) [1].
    Iratumumab
  • HY-P9998

    UB421

    HIV Cancer
    Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection [1] .
    Semzuvolimab
  • HY-P990004

    Tim3 Cancer
    Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 antibody inhibitor. Anti-Mouse TIM-3 Antibody (B8.2C12) is a rat IgG1κ subtype antibody [1].
    Anti-Mouse TIM-3 Antibody (B8.2C12)
  • HY-P99313

    Anti-Human IGHE Recombinant Antibody

    Apoptosis Inflammation/Immunology
    Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research [1].
    Quilizumab
  • HY-P99655

    KB004

    Ephrin Receptor Apoptosis Cancer
    Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 + cells and improves pulmonary fibrosis [1] .
    Ifabotuzumab
  • HY-P99316

    CNTO-136

    Interleukin Related Inflammation/Immunology
    Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis [1] .
    Sirukumab
  • HY-P99340
    Sotrovimab
    1 Publications Verification

    VIR 7831

    SARS-CoV Infection Cancer
    Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease [1] .
    Sotrovimab
  • HY-P99583

    MEDI4893

    Bacterial Infection Inflammation/Immunology
    Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) [1] .
    Suvratoxumab
  • HY-P99410

    AMG 714; PRV-015

    Interleukin Related Inflammation/Immunology
    Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) [1].
    Ordesekimab
  • HY-P99740

    CD276/B7-H3 ADC Antibody Cancer
    Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) [1] .
    Mirzotamab
  • HY-P99925

    REGN421

    Notch Metabolic Disease Cancer
    Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively [1].
    Enoticumab
  • HY-P990084

    IGF-1R Cancer
    Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody [1].
    Veligrotug
  • HY-P990686

    TNF Receptor Inflammation/Immunology
    Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody [1]. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Ispectamab
  • HY-P990729

    CD19 Inflammation/Immunology
    Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody [1]. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Budoprutug
  • HY-P990739

    CTLA-4 Inflammation/Immunology
    Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody [1]. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Evalstotug

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: